CHANGE IN RATINGS
upgraded at KeyBanc. Rating raised to Buy from Hold. Introduces $35 price target. Maintains 2009 EPS estimates of $2.60.
downgraded at Wachovia. Rating lowered to Underperform from Market Perform. Valuation range lowered to $57-$63 from $63-$70. 2009 EPS estimates raised to $2.86 from $2.51.
Charles River Laboratories
downgraded at Goldman Sachs to Sell from Neutral based on potential shortfall in 2009 earnings. See little evidence that business will recover during second half of the year. Believe guidance is at risk. Price target cut to $20 from $25.
downgraded at BofA/Merrill. Rating lowered to Neutral from Buy. Maintains $78 price target and 2009 EPS estimates of $10.50.
upgraded at Goldman Sachs to Buy from Neutral based on valuation and increasing crude oil exposure. Note potential for investor sentiment to turn following recent underperformance, especially if natural gas prices rise. Price target at $74.
upgraded at Goldman Sachs to Neutral from Sell. Order rates are likely nearing a bottom and potential for further margin deterioration appears limited. Note company's strong free cash flow and above-average early cycle exposure. Price target raised to $21 from $15.
downgraded to Underperform at Oppenheimer from perform and price target increased to $16 from $13. Downgrade based on three points: 1) OpCo does not expect that MAR will be able to pay down as much debt as it expects this year; 2) Lodging fundamentals have not indicated improvement to date and are more challenging in 2H09 an 2010, albeit at a lower negative growth rate; and 3) The run-up in the shares as well as the premium valuation compared to the group appear to be unwarranted.
downgraded at Wachovia. Rating lowered to Market Perform from Outperform. Valuation range raised to $19.50-$20.50 from $17.00-$18.00. 2009 EPS estimates raised to $0.96 from $0.92.
upgraded at Morgan Stanley. Rating raised to Overweight from Equal-weight. Price target raised to $24 from $21. Fiscal 2009 EPS estimates raised to $1.68 from $1.65.
downgraded at Credit Suisse to Neutral from Outperform. Believes guidance is achievable but 3G is an overhang. Lowered target price to $20 from $30.
downgraded at BofA/Merrill. Rating lowered to Neutral from Buy. Maintains $9 price target. Maintains 2009 EPS estimates of $0.97.
upgraded at Goldman Sachs to Buy from Sell based on attractive valuation. Believe shares will outperform other life insurers, reducing current discount to book value multiple. Price target raised to $29 from $16.
Upgraded to Buy at Citigroup to buy from hold and price target increased to $100 from $65. Citi expects focus will shift over next few qtrs back to RIMM's unit growth rather than gross margins. RIMM's aggressive promotions (BOGO) open new consumer adoption & accelerate "Smart Becomes Average" view of mainstream adoption vs. former high-end/niche. Enterprise stabilizing & regulatory changes (Mass state encryption) also small help to enterprise units.
upgraded at William Blair to Outperform from Market Perform based on reasonable valuation and slight improvements in end-markets. Note recent uptick in Agricultural Billing Index, suggesting stabilization in construction cycle.
United Parcel Service
downgraded at Credit Suisse to Underperform from Neutral. Cites recovery not at hand and stock is expensive. Raised target price to $41 from $36.
downgraded at Goldman Sachs to Neutral from Buy. shares are up 44% since being upgraded on Jan 22, leaving less potential upside. Maintained $14 target.
This article was written by a staff member of TheStreet.com.